Skip to main content

Advertisement

SpringerLink
Log in

Does CSF p-tau181 help to discriminate Alzheimer’s disease from other dementias and mild cognitive impairment? A meta-analysis of the literature

  • Neurology and Preclinical Neurological Studies - Review Article
  • Published:
Journal of Neural Transmission Aims and scope Submit manuscript

Abstract

To evaluate the clinical importance of cerebrospinal fluid (CSF) phosphorylated tau 181 (p-tau181) in mild cognitive impairment (MCI), Alzheimer’s disease (AD) and other dementias, more specifically: frontotemporal degeneration (FTD), dementia with Lewy bodies (DLB), vascular dementia (VaD) and Parkinson’s disease (PD) with dementia (PDD). Fifty eligible articles were identified by search of databases including PubMed, EMBASE, Elsevier, Springer Link and the Cochrane Library, up to December 2013. The random effects model was used to calculate the standardized mean difference (SMD) with corresponding 95 % CI by STATA 9.0 software. The subgroup analyses were made on the methods or PD with dementia. We found that CSF p-tau181 concentrations were significantly higher in AD compared to MCI [SMD: 0.61, 95 % CI: (0.46, 0.76), z = 8.07, P < 0.001], FTD [SMD: 1.23, 95 % CI: (0.89, 1.56), z = 7.19, P < 0.001], DLB [SMD: 1.08, 95 % CI: (0.80, 1.37), z = 7.41, P < 0.001], PDD [SMD: 1.05, 95 % CI: (0.02, 2.07), z = 2.00, P = 0.045] and VaD [SMD: 1.28, 95 % CI: (0.68, 1.88), z = 4.19, P < 0.001]. Results from this meta-analysis implied that CSF p-tau181 is a good biomarker for discriminating Alzheimer’s disease from other dementias and mild cognitive impairment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

References

  • Alexopoulos P, Guo LH, Kratzer M et al (2011) Impact of SORL1 single nucleotide polymorphisms on Alzheimer’s disease cerebrospinal fluid markers. Dement Geriatr Cognit Disord 32:164–170

    Article  CAS  Google Scholar 

  • Apostolova LG, Hwang KS, Andrawis JP et al (2010) 3D PIB and CSF biomarker associations with hippocampal atrophy in ADNI subjects. Neurobiol Aging 31(8):1284–1303

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Bibl M, Mollenhauer B, Esselmann H et al (2008) Cerebrospinal fluid neurochemical phenotypes in vascular dementias: original data and mini-review. Dement Geriatr Cognit Disord 25(3):256–265

    Article  Google Scholar 

  • Blasko I, Lederer W, Oberbauer H et al (2006) Measurement of thirteen biological markers in CSF of patients with Alzheimer’s disease and other dementias. Dement Geriatr Cognit Disord 21(1):9–15

    Article  Google Scholar 

  • Blennow K (2004) Cerebrospinal fluid protein biomarkers for Alzheimer’s disease. NeuroRx 1(2):213–225

    Article  PubMed Central  PubMed  Google Scholar 

  • Blennow K, Hampel H (2003) CSF markers for incipient Alzheimer’s disease. Lancet Neurol 2:605–613

    Article  CAS  PubMed  Google Scholar 

  • Blennow K, Wallin A, Hager O (1993) Low frequency of postlumbar puncture headache in demented patients. Acta Neurol Scand 88:221–223

    Article  CAS  PubMed  Google Scholar 

  • Blennow K, de Leon MJ, Zetterberg H (2006) Alzheimer’s disease. Lancet 368:387–403

    Article  CAS  PubMed  Google Scholar 

  • Blom ES, Giedraitis V, Zetterberg H et al (2009) Rapid progression from mild cognitive impairment to Alzheimer’s disease in subjects with elevated levels of tau in cerebrospinal fluid and the APOE epsilon4/epsilon4 genotype. Dement Geriatr Cognit Disord 27(5):458–464

    Article  CAS  Google Scholar 

  • Borroni B, Malinverno M, Gardoni F et al (2008) Tau forms in CSF as a reliable biomarker for progressive supranuclear palsy. Neurology 71(22):1796–1803

    Article  CAS  PubMed  Google Scholar 

  • Borroni B, Gardoni F, Parnetti L et al (2009) Pattern of tau forms in CSF is altered in progressive supranuclear palsy. Neurobiol Aging 30:34–40

    Article  CAS  PubMed  Google Scholar 

  • Bouwman FH, van der Flier WM, Schoonenboom NS et al (2007) Longitudinal changes of CSF biomarkers in memory clinic patients. Neurology 69(10):1006–1011

    Article  CAS  PubMed  Google Scholar 

  • Chui HC, Victoroff JI, Margolin D et al (1992) Criteria for the diagnosis of ischemic vascular dementia proposed by the State of California Alzheimer’s Disease Diagnostic and Treatment Centers. Neurology 42:473–480

    Article  CAS  PubMed  Google Scholar 

  • Cohen J (1992) A power primer. Psychol Bull 112:155–159

    Article  CAS  PubMed  Google Scholar 

  • Cummings JL (1988) Intellectual impairment in Parkinson’s disease: clinical, pathologic, and biochemical correlates. J Geriatr Psychiatry Neurol 1(1):24–36

    Article  CAS  PubMed  Google Scholar 

  • de Jong D, Jansen RW, Kremer BP, Verbeek MM (2006) Cerebrospinal fluid amyloid beta42/phosphorylated tau ratio discriminates between Alzheimer’s disease and vascular dementia. J Gerontol A Biol Sci Med Sci 61(7):755–758

    Article  PubMed  Google Scholar 

  • Emre M (2003) Dementia associated with Parkinson’s disease. Lancet Neurol 2(4):229–237

    Article  CAS  PubMed  Google Scholar 

  • Emre M, Aarsland D, Brown R et al (2007) Clinical diagnostic criteria for dementia associated with Parkinson’s disease. Mov Disord 22(12):1689–1707

    Article  PubMed  Google Scholar 

  • Engelborghs S, Maertens K, Vloeberghs E et al (2006) Neuropsychological and behavioural correlates of CSF biomarkers in dementia. Neurochem Int 48:286–295

    Article  CAS  PubMed  Google Scholar 

  • Exalto LG, van der Flier WM, Scheltens P, Biessels GJ (2010) Glycemia and levels of cerebrospinal fluid amyloid and tau in patients attending a memory clinic. J Am Geriatr Soc 58(7):1318–1321

    Article  PubMed  Google Scholar 

  • Frank RA, Galasko D, Hampel H et al (2003) Biological markers for therapeutic trials in Alzheimer’s disease. Neurobiol Aging 24(4):521–536

    Article  PubMed  Google Scholar 

  • Gabelle A, Roche S, Gény C et al (2011) Decreased sAβPPβ, Aβ38, and Aβ40 cerebrospinal fluid levels in frontotemporal dementia. J Alzheimers Dis 26(3):553–563

    CAS  PubMed  Google Scholar 

  • Galimberti D, Venturelli E, Fenoglio C et al (2008) Intrathecal levels of IL-6, IL-11 and LIF in Alzheimer’s disease and frontotemporal lobar degeneration. J Neurol 255:539–544

    Article  CAS  PubMed  Google Scholar 

  • Habert MO, de Souza LC, Lamari F et al (2010) Brain perfusion SPECT correlates with CSF biomarkers in Alzheimer’s disease. Eur J Nucl Med Mol Imaging 37(3):589–593

    Article  PubMed  Google Scholar 

  • Hampel H, Mitchell A, Blennow K et al (2004) Core biological marker candidates of Alzheimer’s disease—perspectives for diagnosis, prediction of outcome and reflection of biological activity. J Neural Transm 111:247–272

    Article  CAS  PubMed  Google Scholar 

  • Hampel H, Blennow K, Shaw LM et al (2010) Total and phosphorylated tau protein as biological markers of Alzheimer’s disease. Exp Gerontol 45:30–40

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Hansson O, Zetterberg H, Buchhave P et al (2006) Association between CSF biomarkers and incipient Alzheimer’s disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 5(3):228–234

    Article  CAS  PubMed  Google Scholar 

  • Henneman WJ, Vrenken H, Barnes J et al (2009) Baseline CSF p-tau levels independently predict progression of hippocampal atrophy in Alzheimer disease. Neurology 73(12):935–940

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Herbert MK, Aerts MB, Kuiperij HB et al (2013) Addition of MHPG to Alzheimer’s disease biomarkers improves differentiation of dementia with Lewy bodies from Alzheimer’s disease but not other dementias. Alzheimers Dement. doi:10.1016/j.jalz.2013.05.1775

    PubMed  Google Scholar 

  • Ibach B, Binder H, Dragon M et al (2006) Cerebrospinal fluid tau and beta-amyloid in Alzheimer patients, disease controls and an age-matched random sample. Neurobiol Aging 27(9):1202–1211

    Article  CAS  PubMed  Google Scholar 

  • Irwin DJ, White MT, Toledo JB et al (2012) Neuropathologic substrates of Parkinson disease dementia. Ann Neurol 72(4):587–598

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Jagust WJ, Landau SM, Shaw LM et al (2009) Relationships between biomarkers in aging and dementia. Neurology 73(15):1193–1199

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Jellinger KA (1996) Diagnostic accuracy of Alzheimer’s disease: a clinicopathological study. Acta Neuropathol 91:219–220

    Article  CAS  PubMed  Google Scholar 

  • Jellinger KA (2009) Formation and development of Lewy pathology: a critical update. J Neurol 256(Suppl 3):270–279

    Article  PubMed  Google Scholar 

  • Jellinger KA, Attems J (2008) Prevalence and impact of vascular and Alzheimer pathologies in Lewy body disease. Acta Neuropathol 115(4):427–436

    Article  PubMed  Google Scholar 

  • Jia JP, Meng R, Sun YX et al (2005) Cerebrospinal fluid tau, Abeta1-42 and inflammatory cytokines in patients with Alzheimer’s disease and vascular dementia. Neurosci Lett 383:12–16

    Article  CAS  PubMed  Google Scholar 

  • Jicha GA, Abner EL, Schmitt FA (2012) Preclinical AD Workgroup staging: pathological correlates and potential challenges. Neurobiol Aging 33(3):622.e1–622.e16

    Article  Google Scholar 

  • Kang JH, Vanderstichele H, Trojanowski JQ, Shaw LM (2012) Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer’s disease. Methods 56(4):484–493

    Article  CAS  PubMed  Google Scholar 

  • Kasuga K, Tokutake T, Ishikawa A et al (2010) Differential levels of alpha-synuclein, beta-amyloid42 and tau in CSF between patients with dementia with Lewy bodies and Alzheimer’s disease. J Neurol Neurosurg Psychiatry 81(6):608–610

    Article  PubMed  Google Scholar 

  • Lanari A, Parnetti L (2009) Cerebrospinal fluid biomarkers and prediction of conversion in patients with mild cognitive impairment: 4-year follow-up in a routine clinical setting. Sci World J 9:961–966

    Article  CAS  Google Scholar 

  • Le Bastard N, Van Buggenhout M, De Leenheir E et al (2007) Low specificity limits the use of the cerebrospinal fluid AB1-42/P-TAU181P ratio to discriminate Alzheimer’s disease from vascular dementia. J Gerontol A Biol Sci Med Sci 62:923–924

    Article  PubMed  Google Scholar 

  • Lewczuk P, Beck G, Ganslandt O et al (2006) International quality control survey of neurochemical dementia diagnostics. Neurosci Lett 409:1–4

    Article  CAS  PubMed  Google Scholar 

  • Mackenzie IR, Foti D, Woulfe J, Hurwitz TA (2008) Atypical frontotemporal lobar degeneration with ubiquitin-positive, TDP-43-negative neuronal inclusions. Brain 131:1282–1293

    Article  PubMed  Google Scholar 

  • McKeith IG, Galasko D, Kosaka K et al (1996) Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 47:1113–1124

    Article  CAS  PubMed  Google Scholar 

  • McKeith IG, Dickson DW, Lowe J et al (2005) Diagnosis and management of dementia with Lewy bodies: third report of the DLB consortium. Neurology 65:1863–1872

    Article  CAS  PubMed  Google Scholar 

  • McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s disease. Neurology 34:939–944

    Article  CAS  PubMed  Google Scholar 

  • Mitchell AJ (2009) CSF phosphorylated tau in the diagnosis and prognosis of mild cognitive impairment and Alzheimer’s disease: a meta-analysis of 51 studies. J Neurol Neurosurg Psychiatry 80:966–975

    Article  CAS  PubMed  Google Scholar 

  • Mollenhauer B, Bibl M, Wiltfang J et al (2006) Total tau protein, phosphorylated tau (181p) protein, beta-amyloid(1-42), and beta-amyloid(1–40) in cerebrospinal fluid of patients with dementia with Lewy bodies. Clin Chem Lab Med 44(2):192–195

    Article  CAS  PubMed  Google Scholar 

  • Mouton-Liger F, Paquet C, Dumurgier J et al (2012) Increased cerebrospinal fluid levels of double-stranded RNA-dependant protein kinase in Alzheimer’s disease. Biol Psychiatry 71:829–835

    Article  CAS  PubMed  Google Scholar 

  • Mulugeta E, Londos E, Ballard C et al (2011) CSF amyloid β38 as a novel diagnostic marker for dementia with Lewy bodies. J Neurol Neurosurg Psychiatry 82(2):160–164

    Article  PubMed  Google Scholar 

  • Neary D, Snowden JS, Gustafson L et al (1998) Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 51:1546–1554

    Article  CAS  PubMed  Google Scholar 

  • Nettiksimmons J, Harvey D, Brewer J et al (2010) Subtypes based on cerebrospinal fluid and magnetic resonance imaging markers in normal elderly predict cognitive decline. Neurobiol Aging 31(8):1419–1428

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Noguchi-Shinohara M, Tokuda T, Yoshita M et al (2009) CSF α-synuclein levels in dementia with Lewy bodies and Alzheimer’s disease. Brain Res 1251:1–6

    Article  CAS  PubMed  Google Scholar 

  • Okonkwo OC, Alosco ML, Griffith HR et al (2010) Cerebrospinal fluid abnormalities and rate of decline in everyday function across the dementia spectrum: normal aging, mild cognitive impairment, and Alzheimer disease. Arch Neurol 67(6):688–696

    Article  PubMed Central  PubMed  Google Scholar 

  • Parnetti L, Lanari A, Silvestrelli G et al (2006) Diagnosing prodromal Alzheimer’s disease: role of CSF biochemical markers. Mech Ageing Dev 127(2):129–132

    Article  CAS  PubMed  Google Scholar 

  • Parnetti L, Tiraboschi P, Lanari A et al (2008) Cerebrospinal fluid biomarkers in Parkinson’s disease with dementia and dementia with Lewy bodies. Biol Psychiatry 64(10):850–855

    Article  CAS  PubMed  Google Scholar 

  • Randall C, Mosconi L, de Leon M et al (2013) Cerebrospinal fluid biomarkers of Alzheimer’s disease in healthy elderly. Front Biosci 18:1150–1173

    Article  CAS  Google Scholar 

  • Ravaglia S, Bini P, Sinforiani E et al (2008) Cerebrospinal fluid levels of tau phosphorylated at threonine 181 in patients with Alzheimer’s disease and vascular dementia. Neurol Sci 29:417–423

    Article  PubMed  Google Scholar 

  • Regeniter A, Kuhle J, Baumann T et al (2012) Biomarkers of dementia: comparison of electrochemiluminescence results and reference ranges with conventional ELISA. Methods 56(4):494–499

    Article  CAS  PubMed  Google Scholar 

  • Riepe MW, Karl J, Tumani H, von Arnim CA (2010) Tau-proteins as gender-specific state markers in amnestic mild cognitive impairment. Dement Geriatr Cognit Disord 30(2):93–100

    Article  CAS  Google Scholar 

  • Roman GC, Tatemichi TK, Erkinjutti T et al (1993) Vascular dementia: diagnostic criteria for research studies-report of the NINDSAIREN International Workshop. Neurology 43(2):250–260

    Article  CAS  PubMed  Google Scholar 

  • Schmand B, Eikelenboom P, van Gool WA et al (2011) Value of neuropsychological tests, neuroimaging, and biomarkers for diagnosing Alzheimer’s disease in younger and older age cohorts. J Am Geriatr Soc 59(9):1705–1710

    Article  PubMed  Google Scholar 

  • Schott JM, Bartlett JW, Barnes J et al (2010) Reduced sample sizes for atrophy outcomes in Alzheimer’s disease trials: baseline adjustment. Neurobiol Aging 31(8):1452–1462

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Seppälä TT, Koivisto AM, Hartikainen P et al (2011) Longitudinal changes of CSF biomarkers in Alzheimer’s disease. J Alzheimers Dis 25(4):583–594

    PubMed  Google Scholar 

  • Shaw LM, Vanderstichele H, Knapik-Czajka M et al (2009) Cerebrospinal fluid biomarker signature in Alzheimer’s disease neuroimaging initiative subjects. Ann Neurol 65(4):403–413

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Sjögren M, Davidsson P, Tullberg M et al (2001) Both total and phosphorylated tau are increased in Alzheimer’s disease. J Neurol Neurosurg Psychiatry 70:624–630

    Article  PubMed Central  PubMed  Google Scholar 

  • Sjögren M, Davidsson P, Wallin A et al (2002) Decreased CSF-beta-amyloid 42 in Alzheimer’s disease and amyotrophic lateral sclerosis may reflect mismetabolism of beta amyloid induced by disparate mechanisms. Dement Geriatr Cognit Disord 13:112–118

    Article  Google Scholar 

  • Sluimer JD, Bouwman FH, Vrenken H et al (2010) Whole-brain atrophy rate and CSF biomarker levels in MCI and AD: a longitudinal study. Neurobiol Aging 31(5):758–764

    Article  CAS  PubMed  Google Scholar 

  • Solé-Padullés C, Lladó A, Bartrés-Faz D et al (2011) Association between cerebrospinal fluid tau and brain atrophy is not related to clinical severity in the Alzheimer’s disease continuum. Psychiatry Res 192(3):140–146

    Article  PubMed  Google Scholar 

  • Spies PE, Slats D, Sjögren JM et al (2010) The cerebrospinal fluid amyloid beta42/40 ratio in the differentiation of Alzheimer’s disease from non-Alzheimer’s dementia. Curr Alzheimer Res 7(5):470–476

    Article  CAS  PubMed  Google Scholar 

  • Sundelöf J, Sundström J, Hansson O et al (2010) Cystatin C levels are positively correlated with both Abeta42 and tau levels in cerebrospinal fluid in persons with Alzheimer’s disease, mild cognitive impairment, and healthy controls. J Alzheimers Dis 21(2):471–478

    PubMed  Google Scholar 

  • Thorsell A, Bjerke M, Gobom J et al (2010) Neurogranin in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer’s disease. Brain Res 1362:13–22

    Article  CAS  PubMed  Google Scholar 

  • Tomlinson BE, Blessed G, Roth M (1970) Observations on brains of demented old people. J Neurol Sci 11:205–242

    Article  CAS  PubMed  Google Scholar 

  • Tosun D, Schuff N, Truran-Sacrey D et al (2010) Relations between brain tissue loss, CSF biomarkers and the ApoE genetic profile: a longitudinal MRI study. Neurobiol Aging 31(8):1340–1354

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • van der Flier WM, Scheltens P (2005) Epidemiology and risk factors of dementia. J Neurol Neurosurg Psychiatry 76(Suppl 5):v2–v7

    Article  PubMed Central  PubMed  Google Scholar 

  • van Harten AC, Kester MI, Visser PJ et al (2011) Tau and p-tau as CSF biomarkers in dementia: a meta-analysis. Clin Chem Lab Med 49(3):353–366

    PubMed  Google Scholar 

  • Verwey NA, Kester MI, van der Flier WM et al (2010) Additional value of CSF amyloid-beta 40 levels in the differentiation between FTLD and control subjects. J Alzheimers Dis 20(2):445–452

    CAS  PubMed  Google Scholar 

  • Wada-Isoe K, Kitayama M, Nakaso K et al (2007) Diagnostic markers for diagnosing dementia with Lewy bodies: CSF and MIBG cardiac scintigraphy study. J Neurol Sci 260:33–37

    Article  PubMed  Google Scholar 

  • Waldemar G, Dubois B, Emre M et al (2007) Recommendations for the diagnosis and management of Alzheimer’s disease and other disorders associated with dementia: EFNS guideline. Eur J Neurol 14:e1–e26

    Article  CAS  PubMed  Google Scholar 

  • Wennström M, Londos E, Minthon L et al (2012) Altered CSF orexin and α-synuclein levels in dementia patients. J Alzheimers Dis 29(1):125–132

    PubMed  Google Scholar 

  • Westin K, Buchhave P, Nielsen H et al (2012) CCL2 is associated with a faster rate of cognitive decline during early stages of Alzheimer’s disease. PLoS One 7(1):e30525

    Article  CAS  PubMed Central  PubMed  Google Scholar 

Download references

Acknowledgments

This study was supported by grants from the Nature Science Foundation of Anhui Province (Grant No. 1208085MH145), Department of Anhui Province Education (Grant No. KJ2011Z161).

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Department of Clinical Laboratory Medicine, School of Public Health, Anhui Medical University, No. 81 Meishan road, Hefei, 230032, Anhui, China

    Wei Tang, Yu-You Yao & Zheng-Yu Wang

  2. AnQing City Affiliated Hospital, Anhui Medical University, No. 81 MeiShan road, Hefei, 230032, Anhui, China

    Qiong Huang

  3. Department of Epidemiology and Statistics, School of Public Health, Anhui Medical University, No. 81 Meishan road, Hefei, 230032, Anhui, China

    Yi-Le Wu

  4. Department of General Surgery, The Second Affiliated Hospital of Anhui Medical University, No. 678 FuRong road, Hefei, 230601, Anhui, China

    Yan Wang

Authors
  1. Wei Tang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Qiong Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yu-You Yao
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yan Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yi-Le Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Zheng-Yu Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yu-You Yao.

Additional information

W. Tang and Q. Huang contributed equally to this work.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tang, W., Huang, Q., Yao, YY. et al. Does CSF p-tau181 help to discriminate Alzheimer’s disease from other dementias and mild cognitive impairment? A meta-analysis of the literature. J Neural Transm 121, 1541–1553 (2014). https://doi.org/10.1007/s00702-014-1226-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00702-014-1226-y

Keywords

Search

Navigation